Systemic Delivery of siRNA Specific for Silencing TLR4 Gene Expression Reduces Diabetic Cardiomyopathy in a Mouse Model of Streptozotocin-Induced Type 1 Diabetes
Open Access
- 13 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 11 (5), 1161-1173
- https://doi.org/10.1007/s13300-020-00802-4
Abstract
Introduction Diabetic cardiomyopathy is a cardiac dysfunction in patients with diabetes which may lead to overt heart failure and death. Toll-like receptor (TLR) signaling triggers diabetic cardiomyopathy through various mechanisms, one of which is the upregulation of TLR4 expression. The aim of this study was to delineate the role of TLR4 in diabetic cardiomyopathy. Methods C57BL/6 mice were injected with streptozotocin to induce diabetes. The experimental and control groups were treated with 5 μg of TLR4 small interfering RNA (siRNA) or scrambled siRNA. Cardiac histopathology was evaluated by hematoxylin and eosin, Sirius red, and immunofluorescence staining after treatment with TLR4 siRNA. The myocardial fibrosis and inflammatory factors were detected by quantitative real-time polymerase chain reaction after treatment with TLR4 siRNA. The myocardial function was evaluated by echocardiography after treatment with TLR4 siRNA. Results Compared with non-diabetic mouse hearts, hypertrophy, fibrosis, inflammation of cardiomyocytes, and myocardial dysfunction were significantly increased in diabetic mice (p < 0.05). Knockdown of TLR4 decreased hypertrophy, fibrosis, inflammation of cardiomyocytes, and myocardial dysfunction (p < 0.05). Cardiomyocytic cross-sectional areas in hearts of TLR4 siRNA-treated diabetic mice were similar to those of the sham-treated mice (p > 0.05). The induction of expression of cardiac fetal genes, beta-myosin heavy chain (β-MHC) and atrial natriuretic peptide (ANP), which are two markers of cardiac hypertrophy, was significantly reduced in TLR4 siRNA-treated hearts compared with controls (p < 0.05). Moreover, siRNA-mediated silencing of TLR4 reduced diabetes-induced collagen deposition (p < 0.05). Paralleled with changes in collagen deposition and the expression of collagen I and collagen III, knockdown of TLR4 also reduced the expression of transforming growth factor-β1 (TGFβ1) mRNA (p < 0.05). The increased expression of intercellular cell adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) was significantly attenuated by TLR4 siRNA treatment in the hearts of diabetic mice (p < 0.05). Furthermore, both fractional shortening (FS) and ejection fraction (EF) values were preserved in TLR4 siRNA-treated diabetic mice compared with control siRNA-treated mice (31.80% ± 2.82% vs. 28.50% ± 5.83% for FS, p < 0.05) (57.95% ± 6.48% vs. 45.34% ± 4.25% for EF, p < 0.05). Conclusion Our study used siRNA to specifically silence TLR4 gene expression in the diabetic mouse heart in vivo and to investigate the role that TLR4 plays in diabetic cardiomyopathy. It is likely that silencing of the TLR4 gene through siRNA could prevent the development of diabetic cardiomyopathy.Keywords
Funding Information
- Karamay projects for scientific and technological cooperation and exchange fund (2018HZ004A)
This publication has 38 references indexed in Scilit:
- Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β‐cell mass in a streptozotocin‐induced mouse model of type 2 diabetesDiabetes, Obesity and Metabolism, 2012
- Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetesAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Elevated plasma levels of TNF-alpha and Interleukin-6 in patients with diastolic dysfunction and glucose metabolism disordersCardiovascular Diabetology, 2009
- Deficiency in TLR4 signal transduction ameliorates cardiac injury and cardiomyocyte contractile dysfunction during ischemiaJournal of Cellular and Molecular Medicine, 2009
- Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heartAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studiesThe Lancet, 2008
- Toll‐like receptor‐4 deficiency attenuates doxorubicin‐induced cardiomyopathy in miceEuropean Journal of Heart Failure, 2008
- Toll-like receptor signaling in the ischemic heartFrontiers in Bioscience-Landmark, 2008
- In Vivo Expression of Proinflammatory Mediators in the Adult Heart after Endotoxin Administration: The Role of Toll‐Like Receptor–4The Journal of Infectious Diseases, 2001
- New type of cardiomyopathy associated with diabetic glomerulosclerosisThe American Journal of Cardiology, 1972